ClinicalTrials.gg
Active, not recruitingNCT03179553HeartBeatUpdated Mar 19, 2024

Heart Beat Variability in Neonatal Encephalopathy

An observational study in Neonatal Encephalopathy, Asphyxia Neonatorum and Hypoxic-Ischemic Encephalopathy, sponsored by Imperial College London. Active, not recruiting at 5 sites in United Kingdom. Open to participants aged 0 Hours to 6 Hours, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-19.

Sponsored by Imperial College London · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
210
Ages
0 Hours to 6 Hours
Sex
All
01

Study summary

This study will find out if analysing heartbeat in babies with brain injury, based on standard clinical monitors, can inform treatment decisions and monitor stress levels in real time

Read the detailed description

BACKGROUND

Hypoxic ischaemic encephalopathy (HIE) is the single most common cause of death and lifelong neurodisability in term babies. Although cooling treatment improves outcomes for these babies, early identification (within six hours of birth) of 'at risk infants' remains challenging. Consequently, not all babies who need treatment will receive it and other babies receive treatment unnecessarily. Furthermore, neuroprotection from cooling may be lost if baby remains stressed during treatment, but accurate methods of measuring stress in babies are lacking.

AIMS

Primary aim:

To examine the accuracy of heartbeat variability (HRV), within six hours of birth, to predict adverse neurodevelopmental outcome at 18 to 22 months in encephalopathic babies.

Secondary aims:

  • To examine the relation between heartbeat variability and stress in encephalopathic babies.
  • To identify clinical interventions associated with reduced heartbeat variability in encephalopathic babies.
  • To describe the trajectory of normal heartbeat variability changes in healthy term babies during the first 24 hours after birth.

METHODS

A total 140 term babies with hypoxic ischaemic encephalopathy will be recruited. The investigators will collect continuous electrocardiography (ECG) data, hourly Neonatal Pain Agitation and Sedation Scale (NPASS) and 12 hourly salivary cortisol, for the first five days after birth. Various clinical interventions, and noise and light levels that the baby is exposed to, for the first 5 days after birth will be be recorded.

The investigators will analyse the raw ECG using Matlab® with in-house algorithms to quantify specific linear and non-linear measures of HRV. All recruited encephalopathic babies will have brain magnetic resonance (MR) imaging and spectroscopy using harmonised protocols and neurodevelopmental assessment, as a part of clinical care, or as a part of MR biomarker studies. This data will be collected and used for the Heartbeat study to examine the association between heart rate variability with brain injury and neurodevelopmental outcome.

In addition, the investigators will collect the ECG data from 100 healthy term babies for the first 24 hours after birth, to describe the trajectory of normal heartbeat variability in healthy term babies.

DATA ANALYSIS AND OUTCOME MEASURES

The prognostic accuracy (sensitivity, specificity, 95% confidence intervals) of early heartbeat variability using optimal cut-off values will be reported for the primary outcome. Logistic regression models adjusted for potential confounders will be used to report secondary outcomes.

POTENTIAL BENEFIT TO PATIENTS

Once the most accurate HRV indices and thresholds are identified, this data can be readily incorporated into a bed side real-time monitoring device. This device may have several clinical implications, including (i) improving access to treatment and the number of babies who benefit from being offered cooling; (ii) avoiding cooling therapy to low risk infants with hypoxic ischaemic encephalopathy (iii) maximising the therapeutic effect of cooling by reducing stress; (iv) enabling tailored neonatal nursing care based on real-time monitoring of neonatal stress and thus improving the long-term outcomes of babies with hypoxic ischaemic encephalopathy.

02

Conditions studied

  • Neonatal Encephalopathy
  • Asphyxia Neonatorum
  • Hypoxic-Ischemic Encephalopathy
03

In context

Asphyxia Neonatorum

106 studies on the registry are indexed under Asphyxia Neonatorum; 19 are open to participants now.

This study's planned enrollment of 210 is close to the median of 200 across 27 observational studies indexed under Asphyxia Neonatorum.

Browse Asphyxia Neonatorum studies →

Lead sponsor

Imperial College London is the lead sponsor of 843 studies on the registry; 180 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Hours to 6 Hours
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Newborn babies within 6h of birth, healthy or with neonatal encephalopathy (mild, moderate or severe)

Eligibility criteria

HIE COHORT

Inclusion Criteria:

  • Full term babies (>36 weeks)
  • Requiring resuscitation at birth due to perinatal asphyxia and/or 5 minute Apgar score \<6.
  • Structured clinical neurological examination (modified Sarnat stage) within six hours of age suggestive of encephalopathy (mild, moderate or severe)
  • Age less than six hours at the time of admission to the neonatal unit

Exclusion Criteria:

  • Babies with lethal congenital malformations or cardiac conditions that could affect heartbeat variability
  • Participation in any controlled trials of medical products (C-TIMPS)

HEALTHY COHORT

Inclusion criteria:

  • Healthy full term babies (>36 weeks) and birth weight between 9th to 91st centile
  • Age less than six hours at the time of study enrolment

Exclusion criteria

  • Babies requiring any medication or phototherapy
  • Perinatal maternal fever
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
210 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • HIE

    Babies admitted to the neonatal unit with suspected mild, moderate or severe hypoxic ischaemic encephalopathy .

  • Healthy

    Babies who are inpatients in the postnatal ward, born following uncomplicated pregnancy and delivery.

06

What researchers measure

Primary outcomes

  1. Prognostic accuracy of HRV to predict adverse neurodevelopment outcome

    Various linear and non-linear HRV indices will be compared with neurodevelopment at 18 to 22 months

    Time frame: 18-22months

Secondary outcomes

  1. Correlation between HRV and salivary cortisol levels

    Various linear and non-linear HRV indices will be compared cortisol levels (measure of stress)

    Time frame: first 5 days of live

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03179553
Responsible party
Sponsor
First posted
Jun 7, 2017
Start date
Aug 15, 2017
Primary completion
Aug 28, 2023
Completion
Nov 28, 2025 (estimated)
Last update
Mar 19, 2024

Study contacts

Sudhin Thayyil
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion